Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia

The clinical efficacy of NK-104, a novel and totally synthetic hydroxymethylglutaryl-coenzyme A reductase inhibitor, was assessed in 30 patients (men/women = 15/15, mean age 51 years) with heterozygous familial hypercholesterolemia. After a placebo phase of >4 weeks, NK-104 was given at an initia...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2000-01, Vol.85 (2), p.178-183
Main Authors: Kajinami, Kouji, Koizumi, Junji, Ueda, Kosei, Miyamoto, Susumu, Takegoshi, Tadayoshi, Mabuchi, Hiroshi
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiovascular disease
Cholesterol
Drug therapy
Enzymes
General and cellular metabolism. Vitamins
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical efficacy of NK-104, a novel and totally synthetic hydroxymethylglutaryl-coenzyme A reductase inhibitor, was assessed in 30 patients (men/women = 15/15, mean age 51 years) with heterozygous familial hypercholesterolemia. After a placebo phase of >4 weeks, NK-104 was given at an initial dose of 2 mg/day for 8 weeks, which was increased to 4 mg/day for a further 8 weeks. As a result of 2 mg/day of NK-104 treatment, mean ± SD of total and low-density lipoprotein cholesterol levels decreased significantly (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00656-6